Form 4 for PCVX Vaxcyte, Inc.
Accepted 2025-04-09 00:00:00 ET · period of report 2025-04-07 · accession 0001649094-25-000049 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-09 | 2025-04-07 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $20.93 | +4,777 | 131.9K | +4% | +$100.0K |
| D | 2025-04-09 | 2025-04-07 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -4,777 | 121.1K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-07 | M | A | 4,777 | $20.93 | 131,950 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-04-07 | M | D | 4,777 | $0.00 | 121,115 | D | $20.93 · — to 2031-03-31 | 4,777 Common Stock | (F1) Stock Option is fully vested and exercisable. |